Skip to Main content

Keywords

Researcher identifiers

Social networks

Number of documents

72

Renaud Sabatier (M.D., Ph.D.)


Department of Medical Oncology - Institut Paoli-Calmettes

CRCM - Centre de Recherche en Cancérologie de Marseille (Aix-Marseille Univ, CENRS, INSERM, Institut Paoli-Calmettes)


Journal articles72 documents

  • Clémence Romeo, Olivia Le Saux, Margaux Jacobs, Florence Joly, Gwenael Ferron, et al.. Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network. Cancers, MDPI, 2022, 14 (2), pp.354. ⟨10.3390/cancers14020354⟩. ⟨hal-03622814⟩
  • Renaud Sabatier, Cécile Vicier, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, et al.. Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. Molecular Oncology, Elsevier, 2022, ⟨10.1002/1878-0261.13188⟩. ⟨hal-03583253⟩
  • Alexandre de Nonneville, F. Bertucci, Éric Lambaudie, Gilles Houvenaeghel, Renaud Sabatier, et al.. Évolution et facteurs associés à la publication des travaux de thèse d’exercice par les internes d’oncologie médicale en France. Bulletin du Cancer, John Libbey Eurotext, 2022, ⟨10.1016/j.bulcan.2022.01.009⟩. ⟨hal-03623519⟩
  • Renaud Sabatier, Cécile Vicier, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, et al.. Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. Molecular Oncology, Elsevier, In press, ⟨10.1002/1878-0261.13188⟩. ⟨hal-03606435⟩
  • Jacques-Olivier Bay, Carole Bouleuc, Nelly Firmin, Virginie Gandemer, Nicolas Magne, et al.. L’année 2021 dans tous ses états : une synthèse digérée. Bulletin du Cancer, John Libbey Eurotext, 2022, 109 (1), pp.8-19. ⟨10.1016/j.bulcan.2021.12.003⟩. ⟨hal-03622801⟩
  • Catherine Evans, Catherine Karine Evans, Renaud Sabatier, Olivier Chinot, Alain Loschi, et al.. Développement des infirmiers en pratique avancée en oncologie et hémato-oncologie en France : état des lieux précoce. Bulletin du Cancer, John Libbey Eurotext, 2022, 109 (2), pp.139-150. ⟨10.1016/j.bulcan.2021.11.009⟩. ⟨hal-03598884⟩
  • Catherine Karine Evans, Renaud Sabatier, Olivier Chinot, Alain Loschi, Sylvie Arnaud, et al.. Développement des infirmiers en pratique avancée en oncologie et hémato-oncologie en France : état des lieux précoce. Bulletin du Cancer, John Libbey Eurotext, 2022, 109 (2), pp.139-150. ⟨10.1016/j.bulcan.2021.11.009⟩. ⟨hal-03622825⟩
  • Ana Oaknin, Lucy Gilbert, Anna Tinker, Jubilee Brown, Cara Mathews, et al.. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study. Journal for Immunotherapy of Cancer, BMJ Publishing Group 2022, 10 (1), pp.e003777. ⟨10.1136/jitc-2021-003777⟩. ⟨hal-03622811⟩
  • Essia Mezni, Renaud Sabatier, Anthony Goncalves, Cécile Vicier. Actualités 2021 sur le cancer du sein localement avancé ou métastatique RH+/HER2−. Bulletin du Cancer, John Libbey Eurotext, 2022, 109 (2), pp.216-225. ⟨10.1016/j.bulcan.2021.12.009⟩. ⟨hal-03622806⟩
  • Alexandre de Nonneville, Christophe Zemmour, Sophie Frank, Florence Joly, Isabelle Ray-Coquard, et al.. Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database. Gynecologic Oncology, Elsevier, 2021, ⟨10.1016/j.ygyno.2021.07.019⟩. ⟨hal-03345277⟩
  • Ana Oaknin, Anna Tinker, Lucy Gilbert, Vanessa Samouëlian, Cara Mathews, et al.. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer. Future Oncology, Future Medicine, 2021, 17 (29), pp.3781-3785. ⟨10.2217/fon-2021-0598⟩. ⟨hal-03622744⟩
  • Alexandre de Nonneville, Christophe Zemmour, Sophie Frank, Florence Joly, Isabelle Ray-Coquard, et al.. Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database. Gynecologic Oncology, Elsevier, 2021, 163 (1), pp.64-71. ⟨10.1016/j.ygyno.2021.07.019⟩. ⟨hal-03622742⟩
  • Leonel Varela Cagetti, Laurence Gonzague-Casabianca, Christophe Zemmour, Eric Lambaudie, Gilles Houvenaeghel, et al.. The impact of modern preoperative high-dose-rate brachytherapy in early-stage cervical cancer. Gynecologic Oncology, Elsevier, 2021, 161 (1), pp.166 - 172. ⟨10.1016/j.ygyno.2021.01.034⟩. ⟨inserm-03649584⟩
  • Cecile Vicier, Patrick Sfumato, Nicolas Isambert, Florence Dalenc, Marie Robert, et al.. TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. European Journal of Cancer, Elsevier, 2021, 159, pp.205 - 214. ⟨10.1016/j.ejca.2021.09.040⟩. ⟨inserm-03647613⟩
  • Renaud Sabatier, Cécile Vicier, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, et al.. 739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial. Annals of Oncology, Elsevier, 2021, 32 (15_suppl), pp.S737-S738. ⟨10.1016/j.annonc.2021.08.1181⟩. ⟨hal-03622737⟩
  • Roxane Mari, Christophe Pomel, Pierre-Emmanuel Colombo, Fabrice Narducci, Séverine Garnier, et al.. Circulating tumor DNA as a noninvasive marker of resectability in ovarian carcinomas.. Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, 39 (15_suppl), pp.5548-5548. ⟨10.1200/JCO.2021.39.15_suppl.5548⟩. ⟨hal-03622754⟩
  • Renaud Sabatier, Jean-Yves Pierga, Hervé Curé, Rakan Abulnaja, Eric Lambaudie, et al.. Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. Cancers, MDPI, 2021, 13 (1), pp.140. ⟨10.3390/cancers13010140⟩. ⟨hal-03622751⟩
  • Sandrine Rousset-Rouviere, Philippe Rochigneux, Anne-Sophie Chrétien, Stéphane Fattori, Laurent Gorvel, et al.. Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology. Biomedicines, MDPI, 2021, 9 (6), pp.632. ⟨10.3390/biomedicines9060632⟩. ⟨hal-03622756⟩
  • Cecile Vicier, Patrick Sfumato, Nicolas Isambert, Florence Dalenc, Marie Robert, et al.. TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. European Journal of Cancer, Elsevier, 2021, 159, pp.205-214. ⟨10.1016/j.ejca.2021.09.040⟩. ⟨hal-03622797⟩
  • Renaud Sabatier, Johan Martin, Cécile Vicier, Mathilde Guérin, Audrey Monneur, et al.. Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer. Journal of Clinical Medicine, MDPI, 2021, 10 (6), pp.1272. ⟨10.3390/jcm10061272⟩. ⟨hal-03622759⟩
  • Ana Oaknin, Anna Tinker, Lucy Gilbert, Vanessa Samouëlian, Cara Mathews, et al.. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer. Future Oncology, Future Medicine, 2021, 17 (29), pp.3781-3785. ⟨10.2217/fon-2021-0598⟩. ⟨hal-03623657⟩
  • François Bertucci, Anthony Gonçalves, Arnaud Guille, José Adelaïde, Séverine Garnier, et al.. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Medicine, BioMed Central, 2021, 13 (1), pp.87. ⟨10.1186/s13073-021-00897-9⟩. ⟨hal-03583277⟩
  • Eric Lambaudie, Jérome Mathis, Christophe Zemmour, Camille Jauffret-Fara, Elie Toni Mikhael, et al.. Prediction of early discharge after gynaecological oncology surgery within ERAS. Surgical Endoscopy, Springer Verlag (Germany), 2020, 34 (5), pp.1985-1993. ⟨10.1007/s00464-019-06974-w⟩. ⟨inserm-03009273⟩
  • Ana Oaknin, Anna Tinker, Lucy Gilbert, Vanessa Samouëlian, Cara Mathews, et al.. Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer. JAMA oncology, American Medical Association, 2020, 6 (11), pp.1766. ⟨10.1001/jamaoncol.2020.4515⟩. ⟨hal-03622783⟩
  • Pauline Corbaux, Renaud Sabatier. Nouvelles AMMs au niveau européen : alpélisib – cancer du sein RH+/HER2− métastatique avec mutation PIK3CA. Bulletin du Cancer, John Libbey Eurotext, 2020, 107 (10), pp.959-960. ⟨10.1016/j.bulcan.2020.07.007⟩. ⟨hal-03622832⟩
  • Nicolas Magné, Renaud Sabatier, Marie Wislez, Thierry André, Manuel Rodrigues, et al.. Florilège des actualités oncologiques internationales en 2019. Bull.Cancer, 2020, 107 (2), pp.148-156. ⟨10.1016/j.bulcan.2020.01.010⟩. ⟨hal-02518020⟩
  • Essia Mezni, Cécile Vicier, Mathilde Guerin, Renaud Sabatier, François Bertucci, et al.. New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?. Cancers, MDPI, 2020, 12 (6), pp.1573. ⟨10.3390/cancers12061573⟩. ⟨hal-03623669⟩
  • Gabrielle Planes-Laine, Philippe Rochigneux, François Bertucci, Anne-Sophie Chrétien, Patrice Viens, et al.. PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. Cancers, MDPI, 2019, 11 (7), pp.1033. ⟨10.3390/cancers11071033⟩. ⟨hal-02533030⟩
  • Roxane Mari, Emilie Mamessier, Eric Lambaudie, Magali Provansal, Daniel Birnbaum, et al.. Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. Cancers, MDPI, 2019, 11 (6), pp.774. ⟨10.3390/cancers11060774⟩. ⟨hal-02152656⟩
  • Florence Daviet, Franck Rouby, Pascale Poullin, Julie Moussi‐francès, Marion Sallée, et al.. Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort. British Journal of Clinical Pharmacology, Wiley, 2019, 85 (2), pp.403-412. ⟨10.1111/bcp.13808⟩. ⟨hal-02120988⟩
  • Renaud Sabatier, Emmanuelle Charafe-Jauffret, Jean-Yves Pierga, Hervé Curé, Eric Lambaudie, et al.. Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. Journal of Clinical Medicine Research, Elmer Press, 2019, 8 (5), pp.612. ⟨10.3390/jcm8050612⟩. ⟨hal-02145624⟩
  • Lorène Seguin, Max Chaffanet, Séverine Garnier, José Adélaïde, Nadine Carbuccia, et al.. Major Response to Carboplatin in a Patient With Metastatic Triple-Negative Breast Cancer With Somatic Mutation of BRCA1 and Loss of RAD51B. JCO precision oncology, American Society of Clinical Oncology, 2019, pp.1-9. ⟨10.1200/po.18.00362⟩. ⟨hal-03623688⟩
  • D. Moro-Sibilot, N. Cozic, M. Pérol, J. Mazieres, J. Otto, et al.. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Annals of Oncology, Elsevier, 2019, 30 (12), pp.1985-1991. ⟨10.1093/annonc/mdz407⟩. ⟨hal-02530381⟩
  • Shuichi Aoki, Koetsu Inoue, Sebastian Klein, Stefan Halvorsen, Jiang Chen, et al.. Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. Cancers, MDPI, 2019, 11 (4), pp.497. ⟨10.3390/cancers11040497⟩. ⟨hal-03583447⟩
  • Renaud Sabatier, Marc Lopez, Arnaud Guille, Emilien Billon, Nadine Carbuccia, et al.. High Response to Cetuximab in a Patient With EGFR -Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer. JCO precision oncology, American Society of Clinical Oncology, 2019, pp.1-8. ⟨10.1200/po.18.00310⟩. ⟨hal-03623686⟩
  • Roxane Mari, Emilie Mamessier, Eric Lambaudie, Magali Provansal, Daniel Birnbaum, et al.. Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. Cancers, MDPI, 2019, 11 (6), pp.774. ⟨10.3390/cancers11060774⟩. ⟨hal-03606425⟩
  • Emanuel Nicolas, François Bertucci, Renaud Sabatier, Anthony Gonçalves. Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. Cancers, MDPI, 2018, 10 (12), pp.506. ⟨10.3390/cancers10120506⟩. ⟨hal-03669695⟩
  • R. Sabatier, S. Garnier, N. Carbuccia, A. Guille, C. Tarpin, et al.. RETROSPHER. ERBB2 amplification detection in the plasma at diagnosis for early high-risk HER2-positive breast cancer. Annals of Oncology, Elsevier, 2018, 29 (6), ⟨10.1093/annonc/mdy316.001⟩. ⟨hal-02143655⟩
  • Renaud Sabatier, Véronique Diéras, Xavier B. Pivot, Etienne Brain, Henri Roche, et al.. Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer. Breast Cancer Research and Treatment, Springer Verlag, 2018, 50 (4), pp.1226-1237. ⟨10.4143/crt.2017.446⟩. ⟨inserm-01985845⟩
  • L. Seguin, M. Chaffanet, R. Sabatier, A. Jose, S. Garnier, et al.. A major response to carboplatin in a metastatic triple-negative breast cancer patient with somatic mutation of BRCA1 and RAD51B: When chemotherapy meets precision medicine. Annals of Oncology, Elsevier, 2018, 29 (6), ⟨10.1093/annonc/mdy314.030⟩. ⟨hal-02143656⟩
  • Renaud Sabatier, Emanuel Nicolas, Maria Paciencia, Annie-Pierre Jonville-Bera, Anne Madroszyk, et al.. Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer. Journal of Geriatric Oncology, Elsevier, 2018, 9 (5), pp.494-500. ⟨10.1016/j.jgo.2018.02.011⟩. ⟨hal-02143604⟩
  • Alexandre de Nonneville, François Bertucci, Pascal Finetti, D. Perrot, M. Nilbert, et al.. Determinants of favorable or unfavorable opinion about euthanasia in a sample of French cancer patients receiving palliative care. BMC Palliative Care, BioMed Central, 2018, 17 (1), pp.104. ⟨10.1186/s12904-018-0357-6⟩. ⟨hal-03583406⟩
  • Mathilde Guérin, Anthony Gonçalves, Yves Toiron, Emilie Baudelet, Matthieu Pophillat, et al.. Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. Oncotarget, Impact journals, 2018, 9 (73), pp.33762-33777. ⟨10.18632/oncotarget.26031⟩. ⟨hal-02145636⟩
  • Alexandre De Nonneville, Renaud Sabatier, Anthony Goncalves, Jean-Marc Extra, Carole Tarpin, et al.. Safety and efficacy of eribulin for ``real-world'' older patients with metastatic breast cancer. Journal of Geriatric Oncology, Elsevier, 2018, 9 (3), pp.281-283. ⟨10.1016/j.jgo.2017.11.003⟩. ⟨hal-02143579⟩
  • Emanuel Nicolas, Francois Bertucci, Renaud Sabatier, Anthony Goncalves. Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. Cancers, MDPI, 2018, 10 (12), ⟨10.3390/cancers10120506⟩. ⟨hal-02143625⟩
  • R. Sabatier, C. Pomel, P-E. Colombo, F. Narducci, S. Garnier, et al.. Circulating tumour DNA as an early marker of recurrence and treatment efficacy in ovarian carcinoma, the CIDOC study. Annals of Oncology, Elsevier, 2018, 29 (6), pp.3. ⟨10.1093/annonc/mdy316.007⟩. ⟨hal-02143654⟩
  • Laurys Boudin, Christian Chabannon, Patrick Sfumato, Renaud Sabatier, François Bertucci, et al.. [Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].. Bulletin du Cancer, John Libbey Eurotext, 2017, 104 (4), pp.332 - 343. ⟨10.1016/j.bulcan.2016.12.007⟩. ⟨hal-01788977⟩
  • Alexandre de Nonneville, Anthony Gonçalves, Christophe Zemmour, Jean Classe, Monique Cohen, et al.. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. Breast Cancer Research and Treatment, Springer Verlag, 2017, 162 (2), pp.307-316. ⟨10.1007/s10549-017-4136-5⟩. ⟨hal-03623719⟩
  • Mathilde Guerin, Keyvan Rezai, Nicolas Isambert, Mario Campone, Aurélie Autret, et al.. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. European Journal of Cancer, Elsevier, 2017, 86, pp.28-36. ⟨10.1016/j.ejca.2017.08.025⟩. ⟨hal-03623711⟩
  • Anthony Gonçalves, François Bertucci, Arnaud Guille, Severine Garnier, José Adelaide, et al.. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. Oncotarget, Impact journals, 2016, 7 (48), pp.79428-79441. ⟨10.18632/oncotarget.12714⟩. ⟨hal-03623724⟩
  • Laurys Boudin, Christian Chabannon, Patrick Sfumato, Renaud Sabatier, François Bertucci, et al.. Corrigendum to “Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation” [Eur J Cancer 57 (April 2016) 118–126]. European Journal of Cancer, Elsevier, 2016, 67, pp.223. ⟨10.1016/j.ejca.2016.09.002⟩. ⟨hal-03623727⟩
  • Laurys Boudin, Anthony Gonçalves, Patrick Sfumato, Renaud Sabatier, François Bertucci, et al.. Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study. American Journal of Cancer, Adis, 2016, 7 (14), pp.2077-2084. ⟨10.7150/jca.15797⟩. ⟨inserm-01987531⟩
  • Renaud Sabatier, Pascal Finetti, Emilie Mamessier, José Adelaide, Max Chaffanet, et al.. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget, Impact journals, 2015, 6 (7), pp.5449-5464. ⟨10.18632/oncotarget.3216⟩. ⟨hal-03583484⟩
  • François Bertucci, Pascal Finetti, Renaud Sabatier, Daniel Birnbaum. The CINSARC signature: Prognostic and predictive of response to chemotherapy?. Cell Cycle, Taylor & Francis, 2014, 9 (19), pp.4025-4027. ⟨10.4161/cc.9.19.13463⟩. ⟨hal-03623803⟩
  • Renaud Sabatier, Pascal Finetti, Arnaud Guille, José Adelaïde, Max Chaffanet, et al.. Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. Molecular Cancer, BioMed Central, 2014, 13, pp.228. ⟨10.2174/156652412798376134⟩. ⟨inserm-01192813⟩
  • Renaud Sabatier, Anthony Gonçalves, François Bertucci. Personalized medicine: Present and future of breast cancer management. Critical Reviews in Oncology/Hematology, Elsevier, 2014, 91 (3), pp.223-233. ⟨10.1016/j.critrevonc.2014.03.002⟩. ⟨hal-03623758⟩
  • Emilie Mamessier, François Bertucci, Renaud Sabatier, Daniel Birnbaum, Daniel Olive. "Stealth" tumors: Breast cancer cells shun NK-cells anti-tumor immunity. OncoImmunology, Taylor & Francis, 2014, 1 (3), pp.366-368. ⟨10.4161/onci.18528⟩. ⟨hal-03583489⟩
  • Anthony Gonçalves, Renaud Sabatier, Emmanuelle Charafe-Jauffret, Marine Gilabert, Magali Provansal, et al.. Cancer du sein triple-négatif : caractéristiques histocliniques et moléculaires, prise en charge et perspectives thérapeutiques. Bulletin du Cancer, John Libbey Eurotext, 2013, 100 (5), pp.453-464. ⟨10.1684/bdc.2013.1740⟩. ⟨hal-03623766⟩
  • Renaud Sabatier, Céline Roussin, Jean-Pierre Riviere, Aurélie Jalaguier, Jocelyne Jacquemier, et al.. Breast Metastasis of a Squamous Cell Carcinoma of the Uterine Cervix Mimicking Inflammatory Breast Cancer. Case Reports in Oncology, Basel : Karger, 2012, 5 (2), pp.464-470. ⟨10.1159/000342255⟩. ⟨hal-03623778⟩
  • Renaud Sabatier, Anthony Gonçalves, François Bertucci, Maria-Antonietta Capiello, Frédérique Rousseau, et al.. Are there candidates for high-dose chemotherapy in ovarian carcinoma?. Journal of Experimental and Clinical Cancer Research, BioMed Central, 2012, 31 (1), pp.87. ⟨10.1186/1756-9966-31-87⟩. ⟨inserm-00765646⟩
  • Renaud Sabatier, Jocelyne Jacquemier, François Bertucci, Benjamin Esterni, Pascal Finetti, et al.. Peritumoural vascular invasion: A major determinant of triple-negative breast cancer outcome. European Journal of Cancer, Elsevier, 2011, 47 (10), pp.1537-1545. ⟨10.1016/j.ejca.2011.02.002⟩. ⟨hal-03623796⟩
  • R Sabatier, Pascal Finetti, J Bonensea, J Jacquemier, J Adelaide, et al.. A seven-gene prognostic model for platinum-treated ovarian carcinomas. British Journal of Cancer, Cancer Research UK, 2011, 105 (2), pp.304-311. ⟨10.1038/bjc.2011.219⟩. ⟨hal-03637781⟩
  • Renaud Sabatier, Pascal Finetti, Emilie Mamessier, Stéphane Raynaud, Nathalie Cervera, et al.. Kinome expression profiling and prognosis of basal breast cancers.. Molecular Cancer, BioMed Central, 2011, 10 (1), pp.86. ⟨10.1186/1476-4598-10-86⟩. ⟨inserm-00614833⟩
  • Renaud Sabatier, Pascal Finetti, José Adelaide, Arnaud Guille, Jean-Paul Borg, et al.. Down-Regulation of ECRG4, a Candidate Tumor Suppressor Gene, in Human Breast Cancer. PLoS ONE, Public Library of Science, 2011, 6 (11), pp.e27656. ⟨10.1371/journal.pone.0027656⟩. ⟨hal-03623789⟩
  • Renaud Sabatier, Pascal Finetti, Emilie Mamessier, Stéphane Raynaud, Nathalie Cervera, et al.. Kinome expression profiling and prognosis of basal breast cancers. Molecular Cancer, BioMed Central, 2011, 10 (1), pp.86. ⟨10.1186/1476-4598-10-86⟩. ⟨hal-03606422⟩
  • L. Mineur, R. Sabatier, S. Kirscher, F. Plat, Y. Goubely, et al.. Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients. Clinics and Research in Hepatology and Gastroenterology, Elsevier, 2011, 35 (2), pp.125-131. ⟨10.1016/j.gcb.2009.11.005⟩. ⟨hal-02649856⟩
  • David Birnbaum, Renaud Sabatier, Emilie Mamessier, Daniel Birnbaum, François Bertucci. Une forme « ariditaire » du cancer de l’ovaire. médecine/sciences, EDP Sciences, 2010, 26 (12), pp.1040-1042. ⟨10.1051/medsci/201026121040⟩. ⟨hal-03583491⟩
  • Renaud Sabatier, Pascal Finetti, Nathalie Cervera, Eric Lambaudie, Benjamin Esterni, et al.. A gene expression signature identifies two prognostic subgroups of basal breast cancer: Multigene prognostic classification of basal breast cancers. Breast Cancer Research and Treatment, Springer Verlag, 2010, 126 (2), pp.407-420. ⟨10.1007/s10549-010-0897-9⟩. ⟨hal-00583558⟩
  • Renaud Sabatier, Corinne Bouvier, Gonzague de Pinieux, Anthony Sarran, Isabelle Brenot-Rossi, et al.. Low-grade extraskeletal osteosarcoma of the chest wall: case report and review of literature.. BMC Cancer, BioMed Central, 2010, 10, pp.645. ⟨10.1186/1471-2407-10-645⟩. ⟨hal-00546735⟩
  • Anthony Gonçalves, Pascal Finetti, Renaud Sabatier, Marine Gilabert, José Adelaïde, et al.. -- mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Research and Treatment, Springer Verlag, 2010, 127 (1), pp.273-281. ⟨10.1007/s10549-010-1199-y⟩. ⟨hal-00594471⟩
  • Renaud Sabatier, José Adélaïde, Pascal Finetti, Anthony Ferrari, Laetitia Huiart, et al.. BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer. Genes, Chromosomes & Cancer, Wiley, 2010, 49 (12), pp.1143-1151. ⟨10.1002/gcc.20822⟩. ⟨hal-03623799⟩
  • Renaud Sabatier, Pascal Finetti, Nathalie Cervera, Daniel Birnbaum, François Bertucci. Gene expression profiling and prediction of clinical outcome in ovarian cancer. Critical Reviews in Oncology/Hematology, Elsevier, 2009, 72 (2), pp.98-109. ⟨10.1016/j.critrevonc.2009.01.007⟩. ⟨hal-03623817⟩